share_log

Keybanc Maintains Overweight on Harvard Bioscience, Raises Price Target to $7

Benzinga ·  Apr 26, 2023 17:13

Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and raises the price target from $5 to $7.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment